Petratherm Ltd

PTR

Petratherm Ltd. engages in the development of mineral exploration projects. The Company’s projects include Mabel Creek Iron-Oxide Copper-Gold, Comet Gold, Comet Rare Earth, Muckanippie, and Woomera and Arcoona Iron-Oxide Copper-Gold (IOCG). The Mabel Creek Project, located approximately 50 kilometers (km) northeast of Coober Pedy in South Australia, is prospective for IOCG and Broken Hill Type (BHT) lead-zinc-silver (Pb-Zn-Ag) mineralization. The Comet Project holds a ground position totaling approximately 1,915 kilometers (km2) in the Northern Gawler Craton of South Australia. The Project consists of exploration license (EL) 6443, EL6633, EL6722, EL6816 and EL6818. The Muckanippie Project comprises two tenements (EL6855 and EL6815) totaling approximately 258 km2 over the central and outer portions of Muckanippie Anorthosite Complex. The Woomera and Arcoona IOCG Project has a landholding of approximately 668 km2 and is located in the province of South Australia.

Prescient Therapeutics Limited

PTX

Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The company is headquartered in South Melbourne, Victoria. The firm is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.